Tumor escape from the immune response: a major hurdle for successful immunotherapy of cancer?
Chouaib
Salem
S
INSERM U487-Immunologie des tumeurs Humaines, Institut Gustave Roussy, Villejuif, France.
D000951:Antigens, Neoplasm / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use; D016923:Cell Death / Q000187:drug effects / Q000235:genetics / Q000276:immunology; D005544:Forecasting; D016158:Genes, p53 / Q000187:drug effects / Q000235:genetics / Q000276:immunology; D042822:Genomic Instability / Q000187:drug effects / Q000235:genetics / Q000276:immunology; D006801:Humans; D007116:Immunization, Passive / Q000379:methods* / Q000639:trends; D016233:Immunotherapy, Active / Q000379:methods* / Q000639:trends; D009369:Neoplasms / Q000276:immunology / Q000628:therapy; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects / Q000276:immunology; D019139:Tumor Escape / Q000187:drug effects / Q000276:immunology
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines